Early-stage cancer probe as well as kit and preparation method thereof

A technology of kits and probes, which is applied in the field of early diagnosis products and their kits and preparations, can solve the problems of concentration, dispersion, specificity, low accuracy, and unpredictable collocation effects, etc., to achieve the realization of Imaging detection, the effect of enhancing the signal-to-noise ratio

Inactive Publication Date: 2021-05-28
港科鹏禾生物(苏州)有限公司
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The disadvantage is that the accuracy of the test is not high, and false positive results require colonoscopy review
[0006] 3. Early marker screening: On the one hand, marker detection is an indirect degree of detection, which cannot directly obtain tumor imaging information; Accuracy is still inconclusive, remains to be seen
[0014] However, the above-mentioned various types of highly expressed substances are different in patient combination, concentration, dispersion, and specificity of organ distribution, and there is no complete and clear prior art in this field to guide the technical staff on which type Substances can be concentrated in tumor tissue in the early stage of cancer, and what type of highly expressed substance cannot be concentrated in tumor tissue in the early stage of cancer; there are many variants of the above-mentioned types of molecules, and the expression of each variant varies with the specific tumor location, tumor Types of correlation differences; antibodies against the above-mentioned types of molecules and their variants form countless combinations with different medical image enhancement agents, different small molecule linkers, and different types of early cancers, as well as unpredictable combinations effect, there is no complete and clear prior art in this field to guide the technicians on what type of highly expressed substance antibody, which specific variant or family member antibody, and which medical image enhancement agent, and which What kind of cancer tissue can the early cancer probe composed of a small molecule linker be successfully enriched with; and the complexity of exogenous synthetic transport in the body, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Early-stage cancer probe as well as kit and preparation method thereof
  • Early-stage cancer probe as well as kit and preparation method thereof
  • Early-stage cancer probe as well as kit and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0083] Example 1 A kind of early cancer probe for nuclear magnetic resonance

[0084] 1. The early cancer probe of this embodiment consists of three parts:

[0085] Part A: antibody against human collagen 1 (purchased from Abcam, catalog number is ab6308);

[0086] Part B: NMR enhancer: Gadodiamide ( figure 2 ); (purchased from GE healthcare, trade name Omniscan);

[0087] Part C: small molecule linker BS (PEG) 5; (purchased from ThermoFisher, product number is 21581)

[0088] 2. The preparation method is:

[0089] (1). Mix collagen 1 antibody (part A), Gadodiamide (part B), and small molecule linker BS (PEG) 5 (part C) in PBS buffer at pH 7.4 in the following proportions

[0090]

[0091]

[0092] (2). React the above mixed solution at 4°C for 30 minutes;

[0093] (3). Stop the reaction: add 50mM (final concentration) Tris·HCl, pH 7.5 to stop the reaction;

[0094] (4). Probe purification: The synthesized early cancer probes were dialyzed (ThermoFisher #88242) to...

Embodiment 2

[0095] Example 2 A kind of early cancer probe for CT

[0096] 1. The early cancer probe of this embodiment consists of three parts:

[0097] Part A: antibody against human collagen 1 (purchased from Abcam, catalog number is ab6308);

[0098] Part B: CT enhancer: Diatrizoate; (purchased from FisherScientific, item number is 737-31-5);

[0099]Part C: small molecule linker EDC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimidehydrochloride); (purchased from ThermoFisher, product number 22980);

[0100] 2. The preparation method is:

[0101] (1).Collagen 1 antibody (A), Diatrizoate (B), and small molecule linker EDC (C) in the reaction solution (0.1M MES (2-[N-morpholino]ethanesulfonicacid), pH4.5-5 ) in the following proportions

[0102]

[0103]

[0104] (2). React at room temperature for 120 minutes;

[0105] (3). Probe purification: The synthesized probe was dialyzed (ThermoFisher#88242) to remove unreacted Diatrizoate and EDC, and replaced with pH7.4 PBS buffer.

Embodiment 3-13

[0106] Embodiment 3-13 A kind of early cancer probe for nuclear magnetic resonance

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to view more

Abstract

The invention relates to the technical field of early diagnosis of cancers by means of antibodies, in particular to a product for early diagnosis of colorectal cancer and the like by means of collagen antibodies and conjugates thereof, and a kit and a preparation method of the product. The early-stage cancer probe provided by the invention consists of three parts: a part A: an antibody aiming at an early-stage cancer-specific target; a part B: a medical image enhancer for nondestructive testing; and a part C: a small molecular linker for connecting the part A to the part B. The early-stage cancer probe can be successfully applied to imaging detection of early colorectal cancer, can be used as a targeting signal enhancer, and solves the technical problem of low signal-to-noise ratio of conventional imaging detection.

Description

technical field [0001] The present invention relates to the technical field of early diagnosis of cancer by means of antibodies, in particular to a product for early diagnosis of colorectal cancer and its kit and preparation method by means of collagen antibodies and conjugates thereof. Background technique [0002] The pathogenesis of colorectal cancer is a long-term process. Early bowel cancer has a good prognosis. The cure rate for stage I and stage II bowel cancer is as high as 90%. As the cancer metastasizes to multiple organs, the patient's prognosis deteriorates dramatically. The 5-year survival rate for stage IV bowel cancer is only 14%. The treatment of advanced colorectal cancer mainly relies on chemotherapy, and the prognosis is poor. Recent cancer immunotherapies, such as PD-1 blockade, are ineffective against most colorectal cancers. Therefore, early screening of colorectal cancer is of great significance to human health. [0003] Screening for colorectal ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K49/04A61K49/16A61K49/22
CPCA61K49/0002A61K49/04A61K49/16A61K49/221
Inventor 金晶
Owner 港科鹏禾生物(苏州)有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap